Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

RedHill Biopharma (RDHL) Return on Sales (2016 - 2023)

RedHill Biopharma has reported Return on Sales over the past 12 years, most recently at 0.33% for Q2 2023.

  • Quarterly Return on Sales rose 32.0% to 0.33% in Q2 2023 from the year-ago period, while the trailing twelve-month figure was 0.01% through Jun 2023, changed 0.0% year-over-year, with the annual reading at 0.27% for FY2025, 28.0% up from the prior year.
  • Return on Sales was 0.33% for Q2 2023 at RedHill Biopharma, up from 0.02% in the prior quarter.
  • Over five years, Return on Sales peaked at 0.33% in Q2 2023 and troughed at 0.07% in Q4 2021.
  • The 5-year median for Return on Sales is 0.01% (2020), against an average of 0.04%.
  • Year-over-year, Return on Sales decreased -15bps in 2021 and then surged 32bps in 2023.
  • A 5-year view of Return on Sales shows it stood at 0.07% in 2019, then crashed by -91bps to 0.01% in 2020, then plummeted by -1036bps to 0.07% in 2021, then increased by 17bps to 0.05% in 2022, then skyrocketed by 704bps to 0.33% in 2023.
  • Per Business Quant, the three most recent readings for RDHL's Return on Sales are 0.33% (Q2 2023), 0.02% (Q1 2023), and 0.05% (Q4 2022).